Search Results

You are looking at 21 - 30 of 87 items for :

  • "Ovarian carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Angela Jain, Paula D. Ryan, and Michael V. Seiden

importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma . Lancet 2001 ; 357 : 176 – 182 . 2 International Collaborative Ovarian Neoplasm Group . Paclitaxel plus carboplatin versus standard

Full access

Mary B. Daly, Robert Pilarski, Jennifer E. Axilbund, Michael Berry, Saundra S. Buys, Beth Crawford, Meagan Farmer, Susan Friedman, Judy E. Garber, Seema Khan, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer K. Litton, Lisa Madlensky, P. Kelly Marcom, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Huma Rana, Gwen Reiser, Mark E. Robson, Kristen Mahoney Shannon, Elizabeth Swisher, Nicoleta C. Voian, Jeffrey N. Weitzel, Alison Whelan, Myra J. Wick, Georgia L. Wiesner, Mary Dwyer, Rashmi Kumar, and Susan Darlow

cell ovarian cancers have also been reported in BRCA1/2 carriers. 10 – 15 Mutations are also associated with nonmucinous ovarian carcinoma as opposed to mucinous. 16 , 17 Mucinous epithelial ovarian carcinomas may be associated with other gene

Full access

Robert J. Morgan Jr, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Matthew A. Powell, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Julian C. Schink, Nelson Teng, Theresa L. Werner, Mary A. Dwyer, and Miranda Hughes

; 23 ( Suppl 10 ): x111 – 117 . 4. McCluggage WG . Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis . Pathology 2011 ; 43 : 420 – 432 . 5. Edge SB Byrd DR Compton CC

Full access

Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng, and Theresa L. Werner

the preferred treatment for recurrent ovarian carcinoma. However, some agents are preferred based on expert opinion (primarily because of decreased toxicity and/or marginally increased effectiveness; see page 97). A meta-analysis of 13 randomized

Full access

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022

Featured Updates to the NCCN Guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Floor J. Backes, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Viola C. Chitiyo, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Gary Leiserowitz, Joyce Liu, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, Sanja Percac-Lima, Steven W. Remmenga, John Schorge, Daphne Stewart, Premal H. Thaker, Roberto Vargas, Andrea Wahner Hendrickson, Theresa L. Werner, Emese Zsiros, Mary A. Dwyer, and Lisa Hang

JF , Touzet S , Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study . Ann Oncol 2005 ; 16 : 1795 – 1800 . 10.1093/annonc/mdi368 16093275 16

Full access

Robert J. Morgan Jr, Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Kian Behbakht, Lee-may Chen, Larry Copeland, Marta Ann Crispens, Maria DeRosa, Oliver Dorigo, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Sanja Percac-Lima, Mario Pineda, Steven C. Plaxe, Matthew A. Powell, Elena Ratner, Steven W. Remmenga, Peter G. Rose, Paul Sabbatini, Joseph T. Santoso, Theresa L. Werner, Jennifer Burns, and Miranda Hughes

invasive ovarian carcinoma, women with borderline epithelial tumors tend to be younger, are often diagnosed with stage I disease, and are candidates for fertility-sparing surgery. 235 , 236 Borderline epithelial tumors are rare tumors and are managed

Full access

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Joyce Liu, Haider Mahdi, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, David M. O’Malley, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Roberto Vargas, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

after ovarian cancer staging . J Minim Invasive Gynecol 2017 ; 24 : 739 – 746 . 28347880 10.1016/j.jmig.2017.03.014 39. Bogani G , Borghi C , Leone Roberti Maggiore U , . Minimally invasive surgical staging in early-stage ovarian carcinoma

Full access

Tarra Evans and Ursula Matulonis

genomic and epigenomic signatures of human cancers, including gynecologic cancers. 7 In 2011, the TCGA Research Network published its results from the genomic evaluation of 489 high-grade serous ovarian carcinomas (HGSOCs) before treatment with systemic

Full access

Rajmohan Murali, Deborah F. Delair, Sarah M. Bean, Nadeem R. Abu-Rustum, and Robert A. Soslow

patients into prognostically distinct groups that may benefit from tailored treatment approaches. 52 Molecular Genetic Findings in Synchronous Endometrial and Ovarian Carcinomas The staging of patients with synchronous endometrial and ovarian

Full access

Deborah K. Armstrong

significant other has received grant/research support from Eisai Inc. and Exelixis Inc. References 1. Gelmon KA Tischkowitz M Mackay H . Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple